natgillin/translations-raw huggingface dataset:
Carfilzomib was not mutagenic in the in vitro bacterial reverse mutation (Ames) test and was not clastogenic in the in vivo mouse bone marrow micronucleus assay.
Karfilzomib nije bio mutagen u in vitro testu reverznih mutacija kod bakterija (Amesov test) i nije bio klastogen u in vivo mikronukleus testu na stanicama koštane srži miševa.
The highest non-severely toxic dose of 0.5 mg/kg in monkeys resulted in interstitial inflammation in the kidney along with slight glomerulopathy and slight heart inflammation.
Najviša doza koja nije bila teško toksična, od 0,5 mg/kg, u majmuna je rezultirala intersticijskom upalom u bubrezima, uz blagu glomerulopatiju i blagu upalu srca.
Study eligibility criteria allowed a small subset of patients with myeloma refractory to bortezomib (n = 118) or lenalidomide (n = 57) to be enrolled.
Kriteriji podobnosti za ispitivanje omogućili su uključivanje u ispitivanje maloj podskupini bolesnika s mijelomom otpornim na bortezomib (n = 118) ili lenalidomid (n = 57).
An effect of Kyprolis on QT interval cannot be excluded (see section 5.1).
Ne može se isključiti učinak lijeka Kyprolis na produljenje QT intervala (vidjeti dio 5.1).
• Difficulty breathing, rapid breathing and/or fingertips and lips looking slightly blue (acute respiratory distress syndrome)
• Otežano disanje, ubrzano disanje i/ili blago plavo obojeni prsti i usnice (akutni respiratorni distres sindrom)
Cases of Progressive Multifocal Leukoencephalopathy (PML) have been reported in patients receiving carfilzomib who have had prior or concurrent immunosuppressive therapy.
Zabilježeni su slučajevi progresivne multifokalne leukoencefalopatije (PML) u bolesnika koji su primali karfilzomib i koji su se prethodno ili istodobno liječili imunosupresivima.
Carfilzomib had antiproliferative and proapoptotic activities in preclinical models in haematologic tumours.
Karfilzomib je imao antiproliferativno i proapoptotičko djelovanje u pretkliničkim modelima hematoloških tumora.
For women taking Kyprolis
Za žene koje uzimaju Kyprolis
PX-171-011 evaluated Kyprolis monotherapy versus a control arm (corticosteroids and cyclophosphamide).
U ispitivanju PX-171-011 procijenjena je monoterapija lijekom Kyprolis u odnosu na kontrolnu skupinu (kortikosteridi i ciklofosfamid).
After reconstitution, 1 mL of solution contains 2 mg of carfilzomib.
Nakon rekonstitucije, 1 ml otopine sadrži 2 mg karfilzomiba.
Kyprolis (mg/m2) Dexamethasone (mg)
Kyprolis (mg/m2) Deksametazon (mg)
Male patients must use effective contraception measures during and for 3 months following treatment if their partner is pregnant or of childbearing potential and not using effective contraception (refer to section 4.6).
Muški bolesnici moraju primjenjivati učinkovite mjere kontracepcije tijekom i 3 mjeseca nakon liječenja, ako je njihova partnerica trudna ili reproduktivne dobi, a ne koristi učinkovitu kontracepciju (pogledajte dio 4.6).
Platelet counts should be monitored frequently during treatment with Kyprolis.
Broj trombocita potrebno je često pratiti tijekom primjene lijeka Kyprolis.
A number of cases of Hepatitis B reactivation have been identified in relation to carfilzomib treatment.
Utvrđeno je više slučajeva reaktivacije hepatitisa B u vezi s liječenjem karfilzomibom.
Serum potassium levels should be monitored monthly, or more frequently during treatment with Kyprolis as clinically indicated and will depend on the potassium levels measured before the start of treatment, concomitant therapy used (e.g. medicinal products known to increase the risk of hypokalaemia) and associated comorbidities.
Tijekom liječenja lijekom Kyprolis potrebno je pratiti razinu kalija u serumu na mjesečnoj razini ili češće, kako je klinički indicirano, što će ovisiti o razinama kalija izmjerenima prije početka liječenja, istodobno primjenjivanim lijekovima (npr. lijekovi za koje je poznato da povećavaju rizik od hipokalijemije) i povezanim komorbiditetima.
Those findings were reported at 6 mg/m2 which are below the recommended dose in humans of 27 mg/m2.
Ovi su rezultati prijavljeni pri dozi od 6 mg/m2, što je manje od preporučene doze od 27 mg/m2 u ljudi.
You must look out for certain symptoms while you are taking Kyprolis to reduce the risk of any problems.
Tijekom uzimanja lijeka Kyprolis morate obraćati pozornost na neke simptome kako bi se smanjio rizik nastanka problema.
• Numbness, tingling, or decreased sensation in hands and/or feet
• Utrnulost, trnci ili smanjen osjet u šakama i/ili stopalima
If you become pregnant while taking Kyprolis, notify your doctor or nurse immediately.
Ako tijekom primjene lijeka Kyprolis zatrudnite, odmah obavijestite svog liječnika ili medicinsku sestru.
25 mg daily Cycles 13 on
25 mg dnevno Ciklus 13. i nadalje
• A side effect called tumour lysis syndrome, which can be caused by the rapid breakdown of tumour cells and may cause irregular heartbeat, kidney failure or abnormal blood test results
• Nuspojava zvana sindrom lize tumora, koju može uzrokovati brza razgradnja tumorskih stanica i koja može uzrokovati nepravilne otkucaje srca, zatajenje bubrega ili abnormalne rezultate krvnih pretraga
Cases of hepatic failure, including fatal cases, have been reported in < 1% of subjects in clinical studies with Kyprolis.
Slučajevi zatajenja jetre, uključujući smrtne slučajeve, prijavljeni su u < 1% ispitanika u kliničkim ispitivanjima lijeka Kyprolis.
Dizziness Peripheral neuropathy Headache
Omaglica Periferna neuropatija Glavobolja
Patients with signs or symptoms of NYHA Class III or IV cardiac failure, recent history of myocardial infarction (in the last 4 months), and in patients with uncontrolled angina or arrhythmias, should have a comprehensive cardiological assessment, prior to starting treatment with Kyprolis.
U bolesnika sa znakovima ili simptomima zatajenja srca NYHA klase III ili IV, nedavnom povijesti infarkta miokarda (u posljednja 4 mjeseca) te bolesnika s nekontroliranom anginom ili aritmijama treba se provesti sveobuhvatna kardiološka procjena prije početka primjene lijeka Kyprolis.
• Redness of the skin
• Svrbež kože
The dose of 2 mg/kg/dose in rats is approximately half the recommended dose in humans of 27 mg/m2 based on BSA.
Doza od 2 mg/kg/dozi u štakora odgovara otprilike polovici preporučene doze od 27 mg/m2 u ljudi, koja se temelji na BSA.
If you are given too much Kyprolis
Ako primite previše lijeka Kyprolis
Patients randomised to the Vd arm could receive bortezomib either by the intravenous (n = 108) or subcutaneous (n = 357) route.
Bolesnici koji su randomizirani u Vd skupinu bortezomib su mogli primiti ili intravenskim (n = 108) ili supkutanim (n = 357) putem.
• Stop dose If recovered to ≥ 10 x 109/L and/or bleeding is controlled continue at same dose level
Ako se vrati na vrijednosti ≥ 10 x 109/l i/ili je krvarenje pod kontrolom, nastavite jednakom dozom
Hypertensive crisis
Hipertenzivna kriza
Experts in the treatment of HBV infection should be consulted, as necessary.
Po potrebi se treba savjetovati sa stručnjacima za liječenje infekcije HBV-om.
Kyprolis causes thrombocytopenia through inhibition of platelet budding from megakaryocytes resulting in a classic cyclical thrombocytopenia with platelet nadirs occurring on day 8 or 15 of each 28-day cycle and usually associated with recovery to baseline by the start of the next cycle.
Kyprolis uzrokuje trombocitopeniju inhibirajući pupanje trombocita iz megakariocita, što je rezultiralo klasičnom cikličkom trombocitopenijom s najnižim vrijednostima trombocita 8. ili 15. dana u svakom 28-dnevnom ciklusu i obično je povezana s oporavkom na početne vrijednosti do početka sljedećeg ciklusa.
In clinical studies, hypertension adverse events occurred in approximately 20% of subjects and 7.5% of subjects had grade ≥ 3 hypertension events, but hypertensive crises occurred in < 0.5% of subjects.
U kliničkim ispitivanjima, hipertenzivni štetni događaji javili su se u otprilike 20% ispitanika i 7,5% ispitanika imalo je događaj hipertenzije 3. ili višeg stupnja, dok se hipertenzivna kriza javila u < 0,5% ispitanika.
Creatinine clearance was stable over time for the majority of patients.
U većine bolesnika, klirens kreatinina je bio stabilan tijekom vremena.
While adequate hydration is required prior to dosing in cycle 1, all patients should be monitored for evidence of volume overload, especially patients at risk for cardiac failure.
S obzirom da je prije doziranja u 1. ciklusu potrebna odgovarajuća hidracija, sve bolesnike mora se pratiti zbog utvrđivanja volumnog preopterećenja, posebno bolesnike s rizikom zatajenja srca.
In clinical studies with Kyprolis, cardiac toxicity and dyspnoea typically occurred early in the course of Kyprolis therapy (see section 4.4).
U kliničkim ispitivanjima lijeka Kyprolis kardiološka toksičnost i dispneja obično su se javile rano u tijeku liječenja lijekom Kyprolis (vidjeti dio 4.4).
Based on high number of cases, plausible mechanism and seriousness of the risk, hepatitis B reactivation is proposed to be added as an adverse drug reaction in the SmPC and PL. A relevant warning should also be included.
Na temelju velikog broja slučajeva, mogućeg mehanizma i ozbiljnosti rizika, predloženo je dodavanje reaktivacije hepatitisa B kao nuspojave u sažetak opisa svojstava lijeka i informacije o lijeku.
Carfilzomib was clastogenic in the in vitro chromosomal aberration test in peripheral blood lymphocytes.
Karfilzomib je bio klastogen u in vitro testu kromosomskih aberacija u limfocitima periferne krvi.
Hypertensive emergency
Hipertenzivna hitnost
Adequate hydration is required before dose administration in cycle 1, especially in patients at high risk of tumour lysis syndrome or renal toxicity.
Prije primjene doze u 1. ciklusu potrebna je odgovarajuća hidracija, posebno u bolesnika s visokim rizikom od sindroma lize tumora ili bubrežne toksičnosti.
Overall, the subject incidence of certain adverse events (including cardiac arrhythmias, cardiac failure (see section 4.4), dyspnoea, leukopenia and thrombocytopenia) in clinical trials with Kyprolis was higher for patients who were ≥ 75 years of age compared to patients who were < 75 years of age.
Sveukupno, incidencija određenih štetnih događaja u ispitanika (uključujući srčane aritmije, zatajenje srca (vidjeti dio 4.4), dispneju, leukopeniju i trombocitopeniju) u kliničkim ispitivanjima lijeka Kyprolis bila je viša za bolesnike u dobi od ≥ 75 godina u usporedbi s bolesnicima u dobi od < 75 godina.
Cases of Hepatitis B Virus (HBV) reactivation have been reported in patients receiving carfilzomib.
Zabilježeni su slučajevi reaktivacije virusa hepatitisa B (HBV) u bolesnika koji su primali karfilzomib.
Following initial doses of carfilzomib at 20 mg/m2, the dose was increased to 27 mg/m2 in study PX-171-009 and to 56 mg/m2 in study 2011-003 (see section 5.1).
Nakon početnih doza karfilzomiba od 20 mg/m2, doza je povećana na 27 mg/m2 u ispitivanju PX-171-009 te na 56 mg/m2 u ispitivanju 2011-003 (vidjeti dio 5.1).
• Inflammation of the colon caused by a bacteria called Clostridium difficile
• Upala crijeva uzrokovana bakterijom Clostridium difficile
Dexamethasone should be administered prior to Kyprolis to reduce the incidence and severity of reactions (see section 4.2).
Deksametazon je potrebno primijeniti prije lijeka Kyprolis kako bi se smanjila incidencija i težina reakcija (vidjeti dio 4.2).
• Serious lung infection (pneumonia)
• Ozbiljna infekcija pluća (upala pluća)
Overall, the subject incidence of certain adverse events (including cardiac failure) in clinical trials was higher for patients who were ≥ 75 years of age compared to patients who were < 75 years of age (see section 4.4).
Sveukupno, u kliničkim ispitivanjima je incidencija pojedinih štetnih događaja po ispitaniku (uključujući zatajenje srca) bila viša u bolesnika u dobi od ≥ 75 godina u usporedbi s bolesnicima u dobi od < 75 godina (vidjeti dio 4.4).
A pre-planned second interim OS analysis was performed after 189 deaths in the Kd arm and 209 deaths in the Vd arm. At the time of the analysis, 80% of the targeted events were registered.
Prethodno planirana druga interim OS analiza učinjena je nakon 189 smrtnih slučajeva u Kd skupini i 209 smrtnih slučajeva u Vd skupini.
Renal function should be assessed at treatment initiation and monitored at least monthly or in accordance with accepted clinical practice guidelines, particularly in patients with lower baseline creatinine clearance (CrCL < 30 mL/min).
Funkciju bubrega potrebno je procijeniti prilikom započinjanja liječenja i pratiti najmanje na mjesečnoj razini ili u skladu s prihvaćenim smjernicama kliničke prakse, posebno u bolesnika s nižim početnim klirensom kreatinina (CrCL < 30 ml/min).
In clinical studies with Kyprolis, cardiac failure was reported in approximately 7% of subjects (5% of subjects had grade ≥ 3 events), myocardial infarction was reported in approximately 2% of subjects (1.5% of subjects had grade ≥ 3 events) and myocardial ischaemia was reported in approximately 1% of subjects (< 1% of subjects had grade ≥ 3 events).
U kliničkim ispitivanjima lijeka Kyprolis, zatajenje srca je bilo prijavljeno u otprilike 7% ispitanika (5% ispitanika imalo je događaj 3. ili višeg stupnja), infarkt miokarda je bio prijavljen u otprilike 2% ispitanika (1,5% ispitanika imalo je događaj 3. ili višeg stupnja), a ishemija miokarda je bila prijavljena u otprilike 1% ispitanika (< 1% ispitanika imalo je događaj 3. ili višeg stupnja).
Carfilzomib may decrease the efficacy of oral contraceptives (refer to section 4.5).
Karfilzomib može smanjiti djelotvornost oralnih kontraceptiva (pogledajte dio 4.5).
• Leg or arm pain or swelling (which could be a symptom of blood clots in the deep veins of the leg or arm), chest pain or shortness of breath (which may be a symptom of blood clots in the lungs)
• Bol ili oticanje nogu ili ruku (što može biti simptom krvnih ugrušaka u dubokim venama nogu ili ruku), bolovi u prsnom košu ili nedostatak zraka (što može biti simptom krvnih ugrušaka u plućima)
Kyprolis in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).
Kyprolis u kombinaciji s lenalidomidom i deksametazonom ili u kombinaciji samo s deksametazonom indiciran je za liječenje odraslih bolesnika s multiplim mijelomom koji su prethodno primili najmanje jednu terapiju (vidjeti dio 5.1).
If tolerated, the dose should be increased on day 8 of cycle 1 to 56 mg/m2 (maximum dose 123 mg).
Ako se doza podnosi treba ju 8. dana 1. ciklusa povećati do 56 mg/m2 (maksimalna doza 123 mg).
Adverse reactions are presented below by system organ class and frequency category (table 5).
Nuspojave su prikazane niže prema klasifikaciji organskih sustava i prema kategoriji učestalosti (Tablica 5).
• For subsequent drops to < 10 x 109/L, follow the same recommendations as above and consider 1 dose level reduction when restarting Kyprolisa
• Za naknadna smanjenja na vrijednosti < 10 x 109/l slijedite iste preporuke kao što je gore opisano i razmotrite smanjenje doze za 1 razinu prilikom ponovnog uvođenja lijeka Kyprolisa
Proportion Surviving
Udio preživljenja
Remove vial from refrigerator just prior to use.
Neposredno prije primjene izvadite bočicu iz hladnjaka.
Thus, there are limited data for Kyprolis in combination with lenalidomide and dexamethasone in patients with creatinine clearance (CrCL < 50 mL/min).
Stoga, su podaci o primjeni lijeka Kyprolis u kombinaciji s lenalidomidom i deksametazonom u bolesnika s klirensom kreatinina (CrCL < 50 ml/min) ograničeni.
• Platelet count < 10 x 109/L or evidence of bleeding with thrombocytopenia (see section 4.4)
• Broj trombocita < 10 x 109/l ili dokaz krvarenja uz trombocitopeniju (vidjeti dio 4.4)
Very common side effects (may affect more than 1 in 10 people)
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 bolesnika)
• Hepatitis B infection activated again (viral inflammation of the liver)
• Ponovno aktiviranje infekcije hepatitisom B (virusna upala jetre)
• For subsequent drops to < 0.5 x 109/L, follow the same recommendations as above and consider 1 dose level reduction when restarting Kyprolisa
• Za naknadna smanjenja na vrijednosti < 0,5 x 109/l slijedite iste preporuke kao što je gore opisano i razmotrite smanjenje doze za 1 razinu prilikom ponovnog uvođenja lijeka Kyprolisa
The most common adverse reactions (occurring in > 20% of subjects) were: anaemia, fatigue, thrombocytopenia, nausea, diarrhoea, pyrexia, dyspnoea, respiratory tract infection, cough and neutropenia.
Najčešće nuspojave (javljaju se u > 20% ispitanika) bile su: anemija, umor, trombocitopenija, mučnina, proljev, pireksija, dispneja, infekcije dišnog sustava, kašalj i neutropenija.
• Cytomegalovirus infection
• Citomegalovirusna infekcija
• Headaches, confusion, seizures (fits), visual loss, and high blood pressure (hypertension), which may be symptoms of a neurologic condition known as posterior reversible encephalopathy syndrome (PRES).
• Glavobolje, smetenost, napadaji, gubitak vida i visok krvni tlak (hipertenzija) koji mogu biti simptomi neurološkog stanja poznatog kao sindrom posteriorne reverzibilne encefalopatije (PRES).
This medicinal product contains 0.3 mmols (7 mg) of sodium per mL of reconstituted solution.
Ovaj lijek sadrži 0,3 mmol (7 mg) natrija po ml rekonstituirane otopine.
• Difficulty breathing, including shortness of breath at rest or with activity or a cough (dyspnoea), rapid breathing, feeling like you can't breathe in enough air, wheezing, or cough, which can be signs of lung toxicity
• Otežano disanje, uključujući nedostatak zraka u mirovanju ili pri aktivnosti ili kašalj (zaduha), ubrzano disanje, osjećaj da ne možete udahnuti dovoljnu količinu zraka, piskanje ili kašalj, što mogu biti znakovi plućne toksičnosti
Patients with New York Heart Association (NYHA) Class III and IV heart failure, recent myocardial infarction, and conduction abnormalities uncontrolled by medicinal products were not eligible for the clinical trials.
New York Heart Association) klase III i IV, nedavnim infarktom miokarda i abnormalnostima provodljivosti koje se ne drže pod kontrolom lijekovima nisu bili podobni za sudjelovanje u kliničkim ispitivanjima.
Cardiac failure, myocardial infarction and myocardial ischaemia
Zatajenje srca, infarkt miokarda i ishemija miokarda
Therefore, resumption of therapy should be discussed with experts in managing HBV.
Stoga o nastavku terapije treba razgovarati sa stručnjacima za liječenje infekcije HBV-om.
Carfilzomib is primarily metabolised via peptidase and epoxide hydrolase activities, and as a result, the pharmacokinetic profile of carfilzomib is unlikely to be affected by concomitant administration of cytochrome P450 inhibitors and inducers.
Karfilzomib se primarno metabolizira putem aktivnosti peptidaze i epoksid hidrolaze, a kao rezultat toga, nije vjerojatno da će na farmakokinetički profil karfilzomiba utjecati istodobna primjena inhibitora i induktora citokroma P450.
When administering in an intravenous bag, use only a 21-gauge or larger gauge needle (0.8 mm or smaller external diameter needle) to withdraw the calculated dose from the vial and dilute into a 50 or 100 mL intravenous bag containing 5% glucose solution for injection.
Kada se primjenjuje u vrećici za infuziju, upotrijebite samo iglu veličine 21G ili više G (0,8 mm ili manjeg vanjskog promjera igle) da izvučete izračunatu dozu iz bočice i razrijedite u vrećici za infuziju od 50 ili 100 ml u kojoj se nalazi 5%-tna otopina glukoze za injekcije.
• Reactivation of the chicken pox virus (shingles) that can cause a skin rash and pain (herpes zoster)
• Reaktiviracija virusa uzročnika vodenih kozica (varicella-zoster virusa), što može uzrokovati kožni osip i bol (herpes zoster)
This medicine contains 0.3 mmol sodium (which is 7 mg sodium) per mL of reconstituted solution.
Ovaj lijek sadrži 0,3 mmol natrija (što odgovara 7 mg natrija) po ml rekonstituirane otopine.
At the higher dose of 56 mg/m2, there was not only a greater inhibition of CT-L subunits (≥ 90%) compared to those at 15 to 20 mg/m2, but also a greater inhibition of other proteasome subunits (LMP7, MECL1, and LMP2).
Pri višoj dozi od 56 mg/m2, ne samo da je u usporedbi s dozama od 15 do 20 mg/m2 postojala veća inhibicija CT-L podjedinica (≥ 90%), već je postojala i veća inhibicija drugih proteasomskih podjedinica (LMP7, MECL1, i LMP2).
PFS months median (95% CI)a
PFS u mjesecima, medijan (95% CI)a
The safety and efficacy of Kyprolis were evaluated in a phase 3, randomised, open-label, multicentre study of Kyprolis plus dexamethasone (Kd) versus bortezomib plus dexamethasone (Vd).
Sigurnost i djelotvornost lijeka Kyprolis procijenjene su u randomiziranom, otvorenom, multicentričnom ispitivanju faze 3 kombinacije lijeka Kyprolis i deksametazona (Kd) naspram kombinacije bortezomiba i deksametazona (Vd).
• Fluid build-up in the lining of the heart (pericardial effusion), symptoms include chest pain or pressure and shortness of breath
• Nakupljanje tekućine u ovojnici srca (perikardni izljev), simptomi uključuju bol ili pritisak u prsnom košu i nedostatak zraka
The 20/27 mg/m2 dose is administered over 10 minutes.
Doza od 20/27 mg/m2 primjenjuje se tijekom 10 minuta.
Ensure that patients are well hydrated before administration of Kyprolis in cycle 1, and in subsequent cycles as needed (see section 4.2).
Osigurajte dovoljnu hidraciju bolesnika prije primjene lijeka Kyprolis u 1. ciklusu, te u sljedećim ciklusima prema potrebi (vidjeti dio 4.2).
Patients who had the following were excluded from the trial: creatinine clearance rates < 50 mL/min, NYHA Class III to IV congestive heart failure, or myocardial infarction within the last 4 months, disease progression during the treatment with a bortezomib-containing regimen, or progression during the first 3 months of initiating treatment with lenalidomide and dexamethasone, or progression at any time during treatment with lenalidomide and dexamethasone if this was the subject's most recent line of therapy.
Iz ispitivanja su bili isključeni bolesnici sa sljedećim: brzina klirensa kreatinina < 50 ml/min, kongestivno zatajenje srca NYHA razreda III do IV ili infarkt miokarda unutar posljednja 4 mjeseca, progresija bolesti tijekom liječenja režimom koji sadrži bortezomib, ili progresija bolesti tijekom prva tri mjeseca od inicijacije liječenja lenalidomidom i deksametazonom, ili progresija bolesti u bilo kojem trenutku liječenja lenalidomidom ili deksametazonom ako je to bila posljednja linija liječenja.
The median OS improved by 7.9 months in patients in the KRd arm compared with those in the Rd arm (see Table 6 and Figure 2).
Kod bolesnika unutar KRd skupine, medijan ukupnog preživljenja (OS) poboljšan je za 7,9 mjeseci u usporedbi s onima u skupini Rd (vidjeti Tablicu 6. i Sliku 2).
As Kyprolis is administered in combination with other medicinal products, refer to their summaries of product characteristics for additional contraindications.
S obzirom da se Kyprolis primjenjuje u kombinaciji s drugim lijekovima, provjerite njihove sažetke opisa svojstava lijeka za informacije o dodatnim kontraindikacijama.
Note: Kyprolis infusion times remain unchanged during dose reduction(s) a. If symptoms do not resolve, discontinue Kyprolis treatment
Napomena: Trajanje infuzije lijeka Kyprolis ostaje nepromijenjeno tijekom smanjenja doze a.